Long-Acting Treatment in Adolescents (LATA): A Randomised Open-label 2-arm 96 Week Trial in Virologically Suppressed HIV-1-positive Adolescents Aged 12-19 Years of Age in Sub-Saharan Africa
Latest Information Update: 03 May 2024
Price :
$35 *
At a glance
- Drugs Cabotegravir (Primary) ; Rilpivirine (Primary) ; Dolutegravir/lamivudine/tenofovir disoproxil fumarate; Dolutegravir/lamivudine/tenofovir-alafenamide
- Indications HIV-1 infections
- Focus Pharmacodynamics
- Acronyms LATA
- 26 Apr 2024 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.
- 26 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2023 Status changed from not yet recruiting to recruiting.